Clinical Overview
Nefazodone was an atypical antidepressant indicated for the treatment of major depressive disorder. Important Note: This medication was largely withdrawn from most markets due to serious hepatotoxicity concerns, including cases of liver failure requiring transplantation and resulting in death. It is no longer available in the United States and most other countries.
Historical Clinical Applications
Nefazodone was used for major depressive disorder, particularly in patients who experienced sexual side effects with SSRIs, as it had minimal impact on sexual function. It was also sometimes used for anxiety disorders and PTSD.
Mechanism and Safety Concerns
Nefazodone blocked serotonin 5-HT2A receptors and inhibited serotonin reuptake, providing antidepressant effects with less sexual dysfunction. However, it carried an unacceptable risk of severe liver toxicity that led to its market withdrawal.
Current Status
Due to hepatotoxicity concerns, nefazodone has been discontinued in most countries. Patients previously on nefazodone should be transitioned to safer alternative antidepressants under medical supervision.
Prescribing Information
Market Status
- DISCONTINUED: Withdrawn from most markets due to hepatotoxicity
- Reason: Cases of liver failure, transplantation, and death
- FDA Boxed Warning: Life-threatening hepatotoxicity
- Current Recommendation: Use alternative antidepressants
Historical Indications
- Major depressive disorder
- Off-label: Anxiety disorders, PTSD
Historical Dosing (when available)
- Initial: 200 mg daily in divided doses
- Target: 300-600 mg daily in divided doses
- Elderly: 100 mg daily initially
Contraindications
- All patients – medication discontinued
- Previously contraindicated in: active liver disease, elevated baseline liver enzymes
Warnings & Precautions
- BLACK BOX WARNING: Life-threatening hepatotoxicity
- Liver failure: Cases requiring transplantation
- Death: Fatal cases reported
- No longer considered safe: Risk outweighs benefits
Alternative Treatments
Recommended Alternatives:
- SSRIs: Sertraline, escitalopram, fluoxetine
- SNRIs: Venlafaxine, duloxetine, desvenlafaxine
- Atypical antidepressants: Bupropion, mirtazapine, trazodone
- For sexual side effects: Bupropion, mirtazapine
Transition Considerations
- Immediate discontinuation required if still prescribed
- Monitor liver function during transition
- Gradual cross-titration to alternative antidepressant
- Consider patient’s depression severity and previous responses
Special Populations
- All Populations: Medication no longer available
- Previous Use: Required extensive liver function monitoring
- Historical Risk: Higher risk in elderly and those with liver disease
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
